Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options
If you suffered losses in Baxter and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK–(BUSINESS WIRE)–$BAX #BAX—Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX).
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
On April 7, 2025, a Missouri news outlet published a report detailing serious safety concerns involving inaccurate infusion rates with Baxter International Inc.’s Novum IQ Large Volume Pump (“Novum LVP”), a device used to deliver intravenous fluids. The report, citing a whistleblower from a local hospital system, alleged that “patients should not be being treated with these pumps. These pumps are not safe.” In response, the hospital system removed all Novum LVPs from use.
On April 24, 2025, Baxter issued warning letters to customers acknowledging a potential under infusion risk with the Novum LVP, disclosing one serious injury linked to the problem. Later, on July 14, 2025, the Company sent a second warning letter reiterating the under infusion risk and adding a new over infusion risk, revealing that it had received 79 reports of serious injuries and two reports of patient deaths associated with the device. The FDA subsequently classified the matter as a Class I recall, its most severe category, indicating a risk of serious injury or death.
Finally, on July 31, 2025, Baxter announced that it was “voluntarily and temporarily pausing shipments and planned installations of the Novum LVP” and stated that it was “unable to currently commit to an exact timing for resuming shipment and installation.”
Following this announcement, Baxter’s stock price dropped $6.24 per share, or 22.4%, falling from its prior close to $21.61 per share on July 31, 2025, thereby harming investors.
To learn more about the Baxter International investigation, go to www.faruqilaw.com/BAX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Contacts
Faruqi & Faruqi, LLP
Josh Wilson
877-247-4292 or 212-983-9330 (Ext. 1310)
